What is claimed is:

Claim 1: Use of an anti-PD-L1 antibody in the manufacture of a medicament for treating biliary tract cancer (BTC) in a patient, wherein the anti-PD-L1 antibody is to be used in combination with chemotherapy to increase overall survival in the patient.

Claim 2: The use of claim 1, wherein the chemotherapy comprises concurrent chemotherapy.

Claim 3: The use of either claim 1 or claim 2, wherein the chemotherapy comprises a platinum-based chemotherapy and/or an antimetabolite-based chemotherapy.

Claim 4: The use of claim 3, wherein the platinum-based chemotherapy is cisplatin or carboplatin.

Claim 5: The use of claim 3, wherein the antimetabolite-based chemotherapy is gemcitabine.

Claim 6: The use of any one of claims 1-5, wherein the anti-PD-L1 antibody is durvalumab, avelumab, sugemalimab or atezolizumab.

Claim 7: The use of any one of claims 1-6, wherein the anti-PD-L1 antibody and/or chemotherapy is to be administered intravenously.

Claim 8: The use of any one of claims 1-7, wherein the anti-PD-L1 antibody is to be administered to the patient every three weeks (Q3W).

Claim 9: The use of any one of claims 1-8, wherein the anti-PD-L1 antibody and a dose of chemotherapy are to be administered concurrently or consecutively.

Claim 10: The use of any one of claims 1-9, wherein a second dose of chemotherapy is to be administered 7 days after the administration of a first dose of chemotherapy.

Claim 11: The use of any one of claims 1-10 comprising a treatment cycle lasting 21 days, wherein:

(a) the anti-PD-L1 antibody and the first dose of chemotherapy are to be administered on day 1 of the treatment cycle, and

(b) the second dose of chemotherapy is to be administered on day 8 of the treatment cycle.

Claim 12: The use of claim 11, where the treatment cycle is to be repeated 1, 2, 3, 4, 5, 6, 7, or 8 times.

Claim 13: The use of any one of claims 1-12, wherein the anti-PD-L1 antibody is to be administered after the completion of the treatment with chemotherapy.

Claim 14: The use of any one of claims 11-13, wherein the anti-PD-L1 antibody is to be administered after the end of the final treatment cycle.

Claim 15: The use of claim 14, wherein the anti-PD-L1 antibody is to be administered once every four weeks (Q4W).

Claim 16: The use of any one of claims 1-15, wherein 1000-2000 mg of the anti-PD-L1 antibody is to be administered to the patient.

Claim 17: The use of claim 16, wherein 1500 mg of the anti-PD-L1 antibody is to be administered to the patient.

Claim 18: The use of any one of claims 1-17, wherein gemcitabine 1000 mg/m^2 and cisplatin 25 mg/m^2 are to be administered to the patient intravenously.

Claim 19: The use of any one of claims 1-18, wherein the biliary tract cancer is unresectable, locally advanced, or metastatic.

Claim 20: The use of any one of claims 1-19, wherein the patient has not been previously treated for BTC.

Claim 21: The use of any one of claims 1-20, wherein the patient developed recurrent disease more than 6 months after surgery with curative intent or more than 6 months after the completion of adjuvant therapy.

Claim 22: The use of any one of claims 1-21, wherein observed toxicities are similar to those commonly seen with either chemotherapy or immunotherapy alone.

Claim 23: Use of an anti-PD-L1 antibody in the manufacture of a medicament for treating biliary tract cancer (BTC) in a patient, wherein the anti-PD-L1 antibody is to be used in combination with chemotherapy to extend progression-free survival in the patient.

Claim 24: The use of claim 23, wherein the chemotherapy comprises concurrent chemotherapy.

Claim 25: The use of either claim 23 or claim 24, wherein the chemotherapy comprises a platinum-based chemotherapy and/or an antimetabolite-based chemotherapy.

Claim 26: The use of claim 25, wherein the platinum-based chemotherapy is cisplatin or carboplatin.

Claim 27: The use of claim 25, wherein the antimetabolite-based chemotherapy is gemcitabine.

Claim 28: The use of any one of claims 23-27, wherein the anti-PD-L1 antibody is durvalumab, avelumab, sugemalimab or atezolizumab.

Claim 29: The use of any one of claims 23-28, wherein the anti-PD-L1 antibody and/or chemotherapy is to be administered intravenously.

Claim 30: The use of any one of claims 23-29, wherein the anti-PD-L1 antibody is to be administered to the patient every three weeks (Q3W).

Claim 31: The use of any one of claims 23-30, wherein the anti-PD-L1 antibody and a dose of chemotherapy are to be administered concurrently or consecutively.

Claim 32: The use of any one of claims 23-31, wherein a second dose of chemotherapy is to be administered 7 days after the administration of a first dose of chemotherapy.

Claim 33: The use of any one of claims 23-32 comprising a treatment cycle lasting 21 days, wherein:

(a) the anti-PD-L1 antibody and the first dose of chemotherapy are to be administered on day 1 of the treatment cycle, and

(b) the second dose of chemotherapy is to be administered on day 8 of the treatment cycle.

Claim 34: The use of claim 11, where the treatment cycle is to be repeated 1, 2, 3, 4, 5, 6, 7, or 8 times.

Claim 35: The use of any one of claims 23-33, wherein the anti-PD-L1 antibody is to be administered after the completion of the treatment with chemotherapy.

Claim 36: The use of any one of claims 23-35, wherein the anti-PD-L1 antibody is to be administered after the end of the final treatment cycle.

Claim 37: The use of claim 36, wherein the anti-PD-L1 antibody is to be administered once every four weeks (Q4W).

Claim 38: The use of any one of claims 32-37, wherein 1000-2000 mg of the anti-PD-L1 antibody is to be administered to the patient.

Claim 39: The use of claim 38, wherein 1500 mg of the anti-PD-L1 antibody is to be administered to the patient.

Claim 40: The use of any one of claims 23-39, wherein gemcitabine 1000 mg/m^2 and cisplatin 25 mg/m^2 are to be administered to the patient intravenously.

Claim 41: The use of any one of claims 23-40, wherein the biliary tract cancer is unresectable, locally advanced, or metastatic.

Claim 42: The use of any one of claims 23-41, wherein the patient has not been previously treated for BTC.

Claim 43: The use of any one of claims 23-42, wherein the patient developed recurrent disease more than 6 months after surgery with curative intent or more than 6 months after the completion of adjuvant therapy.

Claim 44: The use of any one of claims 23-43, wherein observed toxicities are similar to those commonly seen with either chemotherapy or immunotherapy alone.

Claim 45: Use of an anti-PD-L1 antibody in the manufacture of a medicament for treating biliary tract cancer (BTC) in a patient, wherein the anti-PD-L1 antibody is to be used in combination with chemotherapy.

Claim 46: The use of claim 45, wherein the chemotherapy comprises concurrent chemotherapy.

Claim 47: The use of either claim 45 or claim 46, wherein the chemotherapy comprises a platinum-based chemotherapy and/or an antimetabolite-based chemotherapy.

Claim 48: The use of claim 47, wherein the platinum-based chemotherapy is cisplatin or carboplatin.

Claim 49: The use of claim 47, wherein the antimetabolite-based chemotherapy is gemcitabine.

Claim 50: The use of any one of claims 45-49, wherein the anti-PD-L1 antibody is durvalumab, avelumab, sugemalimab or atezolizumab.

Claim 51: The use of any one of claims 45-50, wherein the anti-PD-L1 antibody and/or chemotherapy is to be administered intravenously.

Claim 52: The use of any one of claims 45-51, wherein the anti-PD-L1 antibody is to be administered to the patient every three weeks (Q3W).

Claim 53: The use of any one of claims 45-52, wherein the anti-PD-L1 antibody and a dose of chemotherapy are to be administered concurrently or consecutively.

Claim 54: The use of any one of claims 45-53, wherein a second dose of chemotherapy is to be administered 7 days after the administration of a first dose of chemotherapy.

Claim 55: The use of any one of claims 45-54 comprising a treatment cycle lasting 21 days, wherein:

(a) the anti-PD-L1 antibody and the first dose of chemotherapy are to be administered on day 1 of the treatment cycle; and

(b) the second dose of chemotherapy is to be administered on day 8 of the treatment cycle.

Claim 56: The use of claim 55, where the treatment cycle is to be repeated 1, 2, 3, 4, 5, 6, 7, or 8 times.

Claim 57: The use of any one of claims 45-56, wherein the anti-PD-L1 antibody is to be administered after the completion of the treatment with chemotherapy.

Claim 58: The use of any one of claims 45-57, wherein the anti-PD-L1 antibody is to be administered after the end of the final treatment cycle.

Claim 59: The use of claim 58, wherein the anti-PD-L1 antibody is to be administered once every four weeks (Q4W).

Claim 60: The use of any one of claims 45-59, wherein 1000-2000 mg of the anti-PD-L1 antibody is to be administered to the patient.

Claim 61: The use of claim 60, wherein 1500 mg of the anti-PD-L1 antibody is to be administered to the patient.

Claim 62: The use of any one of claims 45-61, wherein gemcitabine 1000 mg/m^2 and cisplatin 25 mg/m^2 are to be administered to the patient intravenously.

Claim 63: The use of any one of claims 45-62, wherein the biliary tract cancer is unresectable, locally advanced, or metastatic.

Claim 64: The use of any one of claims 45-63, wherein the patient has not been previously treated for BTC.

Claim 65: The use of any one of claims 45-64, wherein the patient developed recurrent disease more than 6 months after surgery with curative intent or more than 6 months after the completion of adjuvant therapy.

Claim 66: The use of any one of claims 45-65, wherein observed toxicities are similar to those commonly seen with either chemotherapy or immunotherapy alone.

Claim 67: An anti-PD-L1 antibody in combination with chemotherapy for use in the treatment of biliary tract cancer (BTC).

Claim 68: An anti-PD-L1 antibody in combination with chemotherapy for use in the treatment of biliary tract cancer (BTC) in a patient, wherein overall survival is increased in said patient.

Claim 69: An anti-PD-L1 antibody in combination with chemotherapy for use in a method of increasing overall survival in a patient with biliary tract cancer (BTC).

Claim 70: An anti-PD-L1 antibody in combination with chemotherapy for use in the treatment of biliary tract cancer (BTC) in a patient, wherein progression-free survival is extended in said patient.

Claim 71: An anti-PD-L1 antibody in combination with chemotherapy for use in a method of extending progression-free survival in a patient with biliary tract cancer (BTC).